GFI1b Antibody [B12K19] | Primary Antibodies

Application: Reactivity: Human, Mouse, Rat, Monkey

Lane 1: HEL, Lane 2: TF-1

Usage Information

Dilution
WB1:1000 FCM1:400-1:1600

Application
WB, FCM

Reactivity
Human, Mouse, Rat, Monkey

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
35 kDa, 42 kDa

Datasheet & SDS

Biological Description

Specificity
GFI1b Antibody [B12K19] detects endogenous levels of total GFI1b protein.

Clone
B12K19

Synonym(s)
Zinc finger protein Gfi-1b; Growth factor independent protein 1B; GFI1B

Background
GFI1B belongs to the GFI1 family of transcriptional repressors essential for hematopoietic development, particularly in erythroid and megakaryocytic lineages. It contains an N-terminal SNAG domain that mediates repression through recruitment of chromatin modifiers like CoREST, LSD1, and HDAC1/2, alongside a C-terminal array of zinc fingers that bind specific DNA motifs in target gene regulatory regions. GFI1B drives transcriptional silencing by assembling these corepressor complexes at promoter and enhancer sites, thereby suppressing genes involved in progenitor proliferation and lineage commitment during hematopoiesis. In hematopoietic stem and progenitor cells, GFI1B integrates with GATA1 to autoregulate its own expression and coordinate differentiation programs, while also modulating TGF-β signaling to restrict bipotent erythroid-megakaryocytic progenitors toward mature cell fates. This repression extends to metabolic pathways, where GFI1B epigenetically controls fatty acid oxidation and oxidative phosphorylation genes, maintaining stem cell dormancy and preventing aberrant proliferation. Within megakaryocyte-erythroid progenitors, GFI1B enforces lineage fidelity by dampening self-renewal signals and promoting terminal maturation, with its absence disrupting red blood cell and platelet production. Dysregulation through mutations or low expression activates pathways like JAK-STAT, MAPK, and ROS signaling, contributing to leukemia progression by favoring blast cell survival and metabolic reprogramming. Tissue-specific expression peaks in hematopoietic compartments, where GFI1B levels decline from stem cells to differentiated progeny except in megakaryocyte precursors.

Background

GFI1B belongs to the GFI1 family of transcriptional repressors essential for hematopoietic development, particularly in erythroid and megakaryocytic lineages. It contains an N-terminal SNAG domain that mediates repression through recruitment of chromatin modifiers like CoREST, LSD1, and HDAC1/2, alongside a C-terminal array of zinc fingers that bind specific DNA motifs in target gene regulatory regions. GFI1B drives transcriptional silencing by assembling these corepressor complexes at promoter and enhancer sites, thereby suppressing genes involved in progenitor proliferation and lineage commitment during hematopoiesis. In hematopoietic stem and progenitor cells, GFI1B integrates with GATA1 to autoregulate its own expression and coordinate differentiation programs, while also modulating TGF-β signaling to restrict bipotent erythroid-megakaryocytic progenitors toward mature cell fates. This repression extends to metabolic pathways, where GFI1B epigenetically controls fatty acid oxidation and oxidative phosphorylation genes, maintaining stem cell dormancy and preventing aberrant proliferation. Within megakaryocyte-erythroid progenitors, GFI1B enforces lineage fidelity by dampening self-renewal signals and promoting terminal maturation, with its absence disrupting red blood cell and platelet production. Dysregulation through mutations or low expression activates pathways like JAK-STAT, MAPK, and ROS signaling, contributing to leukemia progression by favoring blast cell survival and metabolic reprogramming. Tissue-specific expression peaks in hematopoietic compartments, where GFI1B levels decline from stem cells to differentiated progeny except in megakaryocyte precursors.

References
https://pubmed.ncbi.nlm.nih.gov/29326122/ https://pubmed.ncbi.nlm.nih.gov/35804097/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%